<DOC>
	<DOCNO>NCT01453283</DOCNO>
	<brief_summary>Background : - Trabectedin experimental drug kill cancer cell laboratory mouse interfere genetic material ( DNA ) cancer cell . - In adult patient cancer receive trabectedin , tumor grow slow shrank . Objectives : - To determine dose trabectedin give safely child adolescent 24-hour continuous infusion vein . - To determine side effect trabectedin child adolescent . - To study body handle trabectedin measure amount drug bloodstream time dose give . - To measure effect trabectedin DNA white blood cell . - To determine individual 's tumor cell specific protein involve DNA repair pattern gene identify tumor sample might help explain trabectedin reduces tumor individual others . - To study genetic factor may influence way body handle trabectedin . - To see trabectedin beneficial certain type cancer . Eligibility : -Children 4 year 17 year age tumor recur long respond standard treatment . Design : - Patients receive trabectedin 24-hour continuous infusion repeat every 21 day . The first three child enter study receive dose 1.1 mg/m2 . Subsequent group six patient receive high dos ( 1.5 mg/m2 1.7 mg/m2 ) long precede dose well tolerate . Patients enrol low dose level may dose increased next level tolerate low dose well . Treatment may continue long cancer worsen treatment tolerate . - Patients blood draw day 1 , 2 , 3 , 4 , 5 7 first treatment cycle study body handle trabectedin . - A tumor sample obtain prior surgery biopsy examine protein involve DNA repair . - A blood sample drawn look genetic factor may influence body handle trabectedin . - Patients periodic physical examination blood test . MRI CT scan do start therapy every two treatment cycle evaluate tumor .</brief_summary>
	<brief_title>Tabectedin Treat Children Adolescents With Cancer</brief_title>
	<detailed_description>Background : Trabectedin ( ET-743 ) natural product derive marine tunicate Ecteinascidia turbinata . It bind minor groove DNA interact various transcription factor result cell cycle arrest . It also inhibit transcription couple nucleotide excision repair system induce lethal DNA strand break . In preclinical clinical study , trabectedin find active many soft tissue sarcoma include leiomyosarcoma , synovial cell sarcoma , neuroblastoma , rhabdomyosarcoma , melanoma , breast , ovarian , non-small cell lung , renal prostate carcinoma . In adult phase I phase II study , trabectedin well-tolerated dose level 1.9mg/m ( 2 ) /dose common toxicity fatigue , neutropenia , reversible transaminase elevation . Objective response see dos equal great 1.5mg/m ( 2 ) /dose . Trabectedin 1.5mg/m ( 2 ) administer 24-hour continuous intravenous infusion recommend dose schedule adult . A pediatric phase I study trabectedin administer 3-hour infusion complete Children 's Oncology Group . The maximum tolerate dose 1.1 mg/m ( 2 ) . Dose limit toxicity reversible elevation hepatic transaminase . Objectives : Determine maximum tolerate dose ( MTD ) trabectedin administer 24-hour continuous infusion child adolescent relapse refractory solid tumor . Define toxicity profile trabectedin administer 24-hr infusion child adolescent . Describe pharmacokinetics trabectedin administer 24-hr infusion child adolescent . Quantify double strand DNA break peripheral blood mononuclear cell patient receive trabectedin . Evaluate archival formalin fix paraffin embed tumor tissue , available prior biopsy surgical procedure , expression nucleotide excision repair proteins genomic instability marker ( histone gamma-H2AX , phospho-ATM , phospho-Chk2 ) immunohistochemistry Molecular characterization DNA repair gene correlation outcome use mRNA isolate microdissected archival formalin fix , paraffin embed tumor section . Study pharmacogenetics host DNA repair proteins drug metabolize enzyme explore impact host factor trabectedin toxicity . Eligibility : Children great equal 4 year less 17 year age relapse refractory solid tumor . Design : Patients receive trabectedin 24-hour continuous infusion repeat every 21 day . The start dose level 1.1mg/m ( 2 ) /dose escalation 1.5mg/m ( 2 ) /dose 1.7mg/m ( 2 ) /dose . All patient receive dexamethasone pretreatment growth factor support filgrastim pegfilgrastim . The definition dose-limiting hepatic toxicity identical definition use phase I trials adult dose schedule . Pharmacokinetic analysis perform day 1 , 2 , 3 , 4 , 5 7 first treatment cycle . Three six patient enrol first dose level 6 patient enrolled subsequent dose level . Dose escalation base tolerability trabectedin prior dose level . For patient enrol dose level 1 ( 1.1mg/m ( 2 ) ) , intrapatient dose escalation dose level 2 ( 1.5mg/m ( 2 ) ) allow subsequent cycle dose limit toxicity occur low dose level . Total accrual 24 patient .</detailed_description>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>INCLUSION CRITERIA : AGE : great equal 4 year less 17 year age . DIAGNOSIS : Histologically confirm solid tumor , may include limited rhabdomyosarcoma soft tissue sarcoma , Ewing 's sarcoma family tumor , osteosarcoma , neuroblastoma , Wilms ' tumor , hepatic tumor , germ cell tumor , brain tumor exception histologic confirmation require patient optic brainstem glioma . MEASURABLE/EVALUABLE DISEASE : Patients must measurable evaluable disease . PRIOR THERAPY : The patient 's cancer must relapse failed respond frontline curative therapy must potentially curative treatment option available . Patients must fully recover less equal grade 1 acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . Myelosuppressive chemotherapy : The last dose myelosuppressive anticancer drug must least 3 week prior study entry . Growth factor : The last dose growth factor filgrastim epoetin must least one week prior study entry , last dose longacting colony stimulate factor , pegfilgrastim , must 2 week prior study entry . Investigational anticancer agent : The last dose investigational agent must least 30 day prior study entry . Biologic anticancer agent : The last dose nonmyelosuppressive biologic agent treatment patient 's cancer ( example , retinoids ) must least 7 day prior study entry . Radiation therapy : The last dose radiation 25 % marrow contain bone ( pelvis , spine , skull ) must least 4 week prior study entry , TBI craniospinal radiation must complete least 4 month prior study entry . The last dose local palliative radiation must least 2 week prior study entry . Stem Cell Transplantation . Patients must least 2 month postautologous transplant recover treatmentrelated toxicity . Patients receive allogeneic transplant exclude . CONCOMITANT MEDICATIONS : Patients brain tumor must stable taper dose corticosteroid 7 day prior date baseline scan perform purpose assess response therapy study . PERFORMANCE STATUS : Patients must Lansky ( less equal 10 year old ) Karnofsky ( great 10 year old ) score great equal 60 % . HEMATOLOGIC FUNCTION : Peripheral absolute neutrophil count great equal 1,500/microliter platelet count great equal 75,000/microliter independent transfusion , hemoglobin great equal 8 gm/dl ( transfusion permit achieve level ) . HEPATIC FUNCTION : ALT ( SGPT ) AST ( SGOT ) must less equal 2.5 x upper limit normal ( ULN ) . Bilirubin must less equal ULN . If patient Gilbert 's syndrome , normal bilirubin require discuss PI study chair . Alkaline phosphatase must less equal ULN age sex alkaline phosphatase great ULN 5 ' nucleotidase must less equal ULN gammaglutamyl transpeptidase ( GGT ) must less equal 2.5 time ULN eligible . Normal Values Alkaline Phosphatase NIH Clinical Center ( U/L ) : Age 4 6 year normal value ( U/L ) Males 93 309 normal value ( U/L ) Females 96 297 . Age 7 9 year normal value ( U/L ) Males 86 315 normal value ( U/L ) Females 69 325 . Age 10 12 year normal value ( U/L ) Males 42 362 normal value ( U/L ) Females 51 332 . Age 13 15 year normal value ( U/L ) Males 74 390 normal value ( U/L ) Females 50 162 . Age 16 18 year normal value ( U/L ) Males 52 171 normal value ( U/L ) Females 47 119 . OTHER : creatine kinase less equal 2.5 time ULN . RENAL FUNCTION : Ageadjusted serum creatinine OR creatinine clearance great equal 60 mL/min/1.73 ( 2 ) . Age less equal 5 serum creatinine less equal 0.8 ( mg/dl ) . Age great 5 year less equal 10 serum creatinine less equal 1.0 ( mg/dl ) . Age great 10 less equal 15 serum creatinine less equal 1.2 ( mg/dl ) . Age great 15 serum creatinine less equal 1.5 ( mg/dl ) . EXCLUSION CRITERIA : Patients severe uncontrolled infection unrelated systemic illness , judgment Principal Associate Investigator would compromise patient 's ability tolerate trabectedin likely interfere study procedure result . Patients known history xeroderma pigmentosum disease reduce DNA repair . Pregnant breastfeeding female . Sexually active patient must willing use effective form birth control . Patients currently receive investigational agent . Patients receive allogeneic stem cell transplant . Patients prior therapy trabectedin ( ET743 , Yondelis ) .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 4, 2012</verification_date>
	<keyword>DNA Repair</keyword>
	<keyword>Nucleotide Excision Repair</keyword>
	<keyword>Trabectedine</keyword>
	<keyword>Phase I</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Cytotoxic</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Malignant Tumor</keyword>
	<keyword>Rhabdomyosarcoma</keyword>
	<keyword>Ewing Sarcoma</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>Wilm 's Tumor</keyword>
	<keyword>Hepatic Tumor</keyword>
	<keyword>Brain Tumor</keyword>
</DOC>